Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M310Revenue $M14.7Net Margin (%)-225.3Altman Z-Score-6.1
Enterprise Value $M243EPS $-0.5Operating Margin %-229.2Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-226.7Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.8Cash flow > EarningsN
Price/Sales18.95-y EBITDA Growth Rate %-16.2Current Ratio2.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M71.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with THLD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THLDFirst Eagle Investment 2015-06-30 Reduce$3.49 - $4.51
($4.01)
$ 4.348%Reduce 9.60%1,270,768
THLDFirst Eagle Investment 2015-03-31 Add$3.33 - $4.61
($3.99)
$ 4.349%Add 2.06%1,405,768
THLDFirst Eagle Investment 2014-12-31 Add$2.7 - $3.56
($3.02)
$ 4.3444%Add 26.17%1,377,448
THLDFirst Eagle Investment 2014-09-30 Add$3.75 - $5.03
($4.2)
$ 4.343%Add 36.46%1,091,700
THLDFirst Eagle Investment 2014-03-31 Add0.01%$4.34 - $5.72
($4.92)
$ 4.34-12%Add 250.00%700,000
THLDFirst Eagle Investment 2012-12-31 Buy $3.98 - $6.55
($4.67)
$ 4.34-7%New holding200,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THLD is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


THLD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
JAEGER WILFRED EDirector 2015-02-18Buy25,000$3.7515.73view
Davar NipunVice President 2014-10-13Buy3,000$2.9945.15view
YOUNGER WILLIAM H JR10% Owner 2014-10-01Sell242,396$3.7715.12view
WHITE JAMES N10% Owner 2014-10-01Sell239,538$3.7715.12view
SWEET DAVID E10% Owner 2014-10-01Sell229,154$3.7715.12view
Speiser Michael L10% Owner 2014-10-01Sell227,228$3.7715.12view
SHEEHAN ANDREW T10% Owner 2014-10-01Sell230,352$3.7715.12view
Pullara Samuel J III10% Owner 2014-10-01Sell226,657$3.7715.12view
GAITHER JAMES C10% Owner 2014-10-01Sell231,287$3.7715.12view
Dyckerhoff Stefan A10% Owner 2014-10-01Sell226,657$3.7715.12view

Press Releases about THLD :

Quarterly/Annual Reports about THLD:

    News about THLD:

    Articles On GuruFocus.com
    Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Pat Aug 27 2015 
    Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide* Aug 11 2015 
    Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald Healthcare Con Jul 01 2015 
    Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL May 12 2015 
    Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus De Dec 06 2014 
    Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in Dece Nov 25 2014 
    Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevaciz Nov 17 2014 
    Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previo Nov 11 2014 
    Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conferenc Nov 10 2014 
    Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented Nov 06 2014 

    More From Other Websites
    Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in... Aug 27 2015
    Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in... Aug 27 2015
    Threshold Pharmaceuticals, Inc. Earnings Q2, 2015 Aug 26 2015
    Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide*... Aug 11 2015
    Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide*... Aug 11 2015
    2 Biotech Stocks That Could Skyrocket In The Next 12 Months Aug 10 2015
    THRESHOLD PHARMACEUTICALS INC Financials Aug 06 2015
    10-Q for Threshold Pharmaceuticals, Inc. Aug 01 2015
    THLD: Update on 2Q15 Financials Jul 31 2015
    Threshold Pharmaceuticals posts 2Q loss Jul 30 2015
    Threshold Pharmaceuticals posts 2Q loss Jul 30 2015
    Threshold Pharmaceuticals Reports Second Quarter 2015 Financial and Operational Results Jul 30 2015
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2015
    Threshold Pharmaceuticals Reports Second Quarter 2015 Financial and Operational Results Jul 30 2015
    Cantor Still Expects Threshold Pharma To More Than Triple, Says 2016 Will Be 'Data Rich' Year Jul 02 2015
    Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald Healthcare... Jul 01 2015
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 10 2015
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 01 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK